Mycenax Biotech Inc. (4726.TWO)

TWD 31.6

(2.6%)

Market Cap (In TWD)

6.52 Billion

Revenue (In TWD)

652.62 Million

Net Income (In TWD)

-682.84 Million

Avg. Volume

361.44 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
34.9-65.2
PE
-13.92
EPS
-2.27
Beta Value
1.061
ISIN
TW0004726005
CUSIP
-
CIK
-
Shares
206615000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Pei-Jiun Chen
Employee Count
-
Website
https://www.mycenax.com.tw
Ipo Date
2012-06-20
Details
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.